A placebo-controlled comparison of the efficiency of triple- and monotherapy in category III B chronic pelvic pain syndrome (CPPS)
- PMID: 17084960
- DOI: 10.1016/j.eururo.2006.09.036
A placebo-controlled comparison of the efficiency of triple- and monotherapy in category III B chronic pelvic pain syndrome (CPPS)
Abstract
Objectives: To perform a prospective, placebo-controlled study to examine the efficacy of alpha-blocker compared with triple therapy (alpha-blocker, anti-inflammatory, and muscle relaxant) in the treatment of Category IIIB chronic pelvic pain syndrome (Category IIIB CPPS).
Materials and methods: The study was conducted between September 2004 and December 2005, and included 90 treatment naïve patients, aged 22-42 yr (mean age: 29.1+/-5.2) with Category IIIB CPPS, who were randomized into three groups: group 1, alpha-blocker; group 2, combination of alpha-blocker, anti-inflammatory, and muscle relaxant; group 3, placebo once daily. The patients were treated for 6 mo and were followed up for a further 6 mo. Changes from baseline in the total and domain scores of the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) were evaluated. The primary criterion for response was scoring <or=2 on the NIH-CPSI quality of life item. The secondary criterion for response was >50% reduction in NIH-CPSI pain score.
Results: The NIH-CPSI initial and sixth-month total scores were 23.1 and 10.7, respectively, in group 1, and 21.9 and 9.2, respectively, in group 2. The initial and sixth-month scores remained stable in group 3 (22.9 and 21.9, respectively). There was no statistically significant difference between two treatment arms with respect to efficiency of treatment (p>0.05). The responses in groups 1 and 2 were found durable at the end of 12 mo.
Conclusions: We found that alpha-blocker monotherapy was as effective and safe as triple therapy in the treatment of Category IIIB CPPS.
Similar articles
-
Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination.Urol Int. 2008;80(2):157-61. doi: 10.1159/000112606. Epub 2008 Mar 19. Urol Int. 2008. PMID: 18362485 Clinical Trial.
-
Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial.J Urol. 2003 Feb;169(2):592-6. doi: 10.1097/01.ju.0000042927.45683.6c. J Urol. 2003. PMID: 12544314 Clinical Trial.
-
More effects of extracorporeal magnetic innervation and terazosin therapy than terazosin therapy alone for non-inflammatory chronic pelvic pain syndrome: a pilot study.Prostate Cancer Prostatic Dis. 2006;9(3):261-5. doi: 10.1038/sj.pcan.4500881. Epub 2006 May 9. Prostate Cancer Prostatic Dis. 2006. PMID: 16683008 Clinical Trial.
-
Identification, pharmacologic considerations, and management of prostatitis.Am J Geriatr Pharmacother. 2011 Feb;9(1):37-48. doi: 10.1016/j.amjopharm.2011.02.005. Am J Geriatr Pharmacother. 2011. PMID: 21459307 Review.
-
Role of alpha1-blockers in chronic prostatitis syndromes.BJU Int. 2008 Mar;101 Suppl 3:11-6. doi: 10.1111/j.1464-410X.2008.07496.x. BJU Int. 2008. PMID: 18307680 Review.
Cited by
-
Evolving Role of Silodosin for the Treatment of Urological Disorders - A Narrative Review.Drug Des Devel Ther. 2022 Aug 26;16:2861-2884. doi: 10.2147/DDDT.S373659. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 36051157 Free PMC article. Review.
-
Oral pharmacological treatments for chronic prostatitis/chronic pelvic pain syndrome: A systematic review and network meta-analysis of randomised controlled trials.EClinicalMedicine. 2022 May 20;48:101457. doi: 10.1016/j.eclinm.2022.101457. eCollection 2022 Jun. EClinicalMedicine. 2022. PMID: 35706494 Free PMC article.
-
Contemporary Management of Chronic Prostatitis.Cureus. 2021 Dec 7;13(12):e20243. doi: 10.7759/cureus.20243. eCollection 2021 Dec. Cureus. 2021. PMID: 35004057 Free PMC article. Review.
-
Diagnostic and Management Strategies for Patients with Chronic Prostatitis and Chronic Pelvic Pain Syndrome.Drugs Aging. 2021 Oct;38(10):845-886. doi: 10.1007/s40266-021-00890-2. Epub 2021 Sep 29. Drugs Aging. 2021. PMID: 34586623 Review.
-
Clinical Efficacy of Multi-Focal Low-Intensity Extracorporeal Shockwave Therapy in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Prospective-Randomized, Double Blind, Placebo-Controlled Study.World J Mens Health. 2022 Oct;40(4):678-685. doi: 10.5534/wjmh.210078. Epub 2021 Jul 14. World J Mens Health. 2022. PMID: 34448376 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources